Key Points
- Insider sale: Director Joshua Smiley sold 9,614 shares on April 2 at an average price of $20.39 for about $196,029, trimming his stake by 7.38% to 120,619 shares (worth ~$2.46M).
- Recent results show Zai Lab reported a quarter EPS of ($0.50) with a negative net margin (38.15%) and negative ROE (22.81%); the company has a market cap of ~$2.30B and a 52‑week range of $15.96–$44.34.
- Analyst sentiment is mixed but leans positive overall, with a MarketBeat consensus of "Moderate Buy" and an average price target of $50, while individual ratings range from Strong Buy to Sell.
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CFO Yajing Chen sold 5,199 shares of Zai Lab stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $20.39, for a total transaction of $106,007.61. Following the sale, the chief financial officer owned 32,558 shares of the company's stock, valued at approximately $663,857.62. The trade was a 13.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Yajing Chen also recently made the following trade(s):
- On Friday, March 13th, Yajing Chen sold 1,703 shares of Zai Lab stock. The stock was sold at an average price of $18.63, for a total value of $31,726.89.
Zai Lab Price Performance
NASDAQ ZLAB opened at $20.41 on Friday. Zai Lab Limited Unsponsored ADR has a 1-year low of $15.96 and a 1-year high of $44.34. The company has a market capitalization of $2.30 billion, a P/E ratio of -12.68 and a beta of 0.86. The business has a 50 day moving average price of $18.67 and a 200 day moving average price of $21.83.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its earnings results on Saturday, February 14th. The company reported ($0.50) EPS for the quarter. The firm had revenue of $127.60 million for the quarter. Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%. On average, research analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of equities research analysts recently commented on the stock. Cantor Fitzgerald lowered their price objective on shares of Zai Lab from $55.00 to $37.00 and set an "overweight" rating on the stock in a research note on Friday, February 27th. UBS Group assumed coverage on shares of Zai Lab in a research report on Wednesday, January 7th. They set a "buy" rating and a $35.00 target price for the company. Zacks Research downgraded shares of Zai Lab from a "hold" rating to a "strong sell" rating in a report on Friday, January 23rd. JPMorgan Chase & Co. lowered their price target on shares of Zai Lab from $39.00 to $32.00 and set an "overweight" rating on the stock in a research report on Wednesday, March 18th. Finally, Jefferies Financial Group upgraded Zai Lab to a "strong-buy" rating in a research report on Monday, January 19th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $50.00.
Read Our Latest Analysis on ZLAB
Institutional Trading of Zai Lab
A hedge fund recently raised its stake in Zai Lab stock. SG Americas Securities LLC boosted its position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) by 6.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 10,396 shares of the company's stock after purchasing an additional 642 shares during the quarter. SG Americas Securities LLC's holdings in Zai Lab were worth $183,000 as of its most recent filing with the Securities and Exchange Commission. 41.65% of the stock is owned by hedge funds and other institutional investors.
About Zai Lab
(
Get Free Report)
Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company's end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.
The company's marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton's tyrosine kinase inhibitor approved for several B-cell malignancies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
